US Gives Boost To Materials Genome Initiative 24/06/2013 by Intellectual Property Watch Leave a Comment The Obama administration and academic and industry partners today announced their commitment to support the Materials Genome Initiative (MGI), a public-private endeavor whose aim is to reduce the time required to develop novel materials that can “fuel advanced manufacturing and bolster the 21st century American economy.”
South Africa A Leader In Renewable Energy, Lagging In IP Rights 24/06/2013 by Linda Daniels for Intellectual Property Watch Leave a Comment Leader of the newly formed Renewables Club and rated as a world leader in the green energy race, South Africa has done little to secure this advantage with intellectual property rights of its own.
Harvard Professor A Flag Bearer For Agricultural Innovation, Biotechnologies In Africa 21/06/2013 by Catherine Saez, Intellectual Property Watch 2 Comments A Harvard University professor known for advancing global development issues hails the merits of agricultural innovation, including biotechnologies, as the unique solution to food security.
Members Of US Congress Seek Pressure On India Over IP Rights 20/06/2013 by William New, Intellectual Property Watch 1 Comment A large portion of the United States Congress this week signed on to a letter to President Obama criticising India for its treatment of intellectual property rights.
Asia-Pacific Region Vies For Biotechnology Industry Opportunities 20/06/2013 by Daria Kim for Intellectual Property Watch Leave a Comment Hong Kong – A recent conference here looked at the evolving biotechnology landscape in the Asia-Pacific region as well as prospects for networking and raising capital for early stage life science innovation.
European Commission Fines Pharma Companies For Payments To Delay Generic Entry 19/06/2013 by Brittany Ngo for Intellectual Property Watch 1 Comment The European Commission (EC) has fined Danish pharmaceutical company Lundbeck as well as eight other generic manufacturers for delaying market entry of generic medicines by way of patent settlement agreements (also known as “pay-for-delay” agreements).
EIFL Guide To The European Orphan Works Directive 19/06/2013 by Intellectual Property Watch Leave a Comment A guide to key provisions and limitations of the European Union directive on permitted uses of orphan works – those whose creators cannot be found – has been published by the Electronic Information for Libraries (EIFL).
US Businesses Launch Coalition For Fair Trade With India 18/06/2013 by Kelly Burke for Intellectual Property Watch 2 Comments A new coalition of United States business groups, called the Alliance for Fair Trade with India (ATFI), launched today to take aim against what they say are discriminatory trade practices in India against US exports.
G8 Hails Trade Deals, Nods To WTO, Issues Declaration On Open Data 18/06/2013 by Monika Ermert for Intellectual Property Watch Leave a Comment In their traditional communiqué, Group of Eight countries at their annual summit welcomed ongoing efforts to negotiate bilateral and multilateral trade deals which they say will allow them to overcome economic uncertainties and shoulder the responsibility to support prosperity worldwide.
US Supreme Court Rules On Pharma Payments To Delay Generic Drugs On Market 17/06/2013 by Catherine Saez, Intellectual Property Watch Leave a Comment The United States Supreme Court in a five to three decision today found that settlement agreements by branded pharmaceutical companies involving payments to generic companies to delay their cheaper drugs’ entry into the market may not be immune from antitrust scrutiny but are not “presumptively” unlawful. The case was sent back to lower court.